Rob Silva, PhD

Dr. Silva is an accomplished neuroscientist and drug development executive with over 20 years of experience in research and pharmaceutical development leading global drug development teams to advance treatments in psychiatric and neurological indications from preclinical through Phase III. He has led several successful development programs resulting in multiple global marketing approvals for CNS products LATUDA® and FINTEMPLA® across schizophrenia, bipolar disorder, Lennox-Gastaut Syndrome, and Dravet Syndrome. In addition to his prior role as Global Head of Development at Mind Medicine, he has held executive and director-level leadership positions at Noema Pharma, UCB, Ipsen Bioscience, and Sunovion Pharmaceuticals. Dr. Silva began his drug development career as a Clinical Scientist at Merck after completing his post-doctoral fellowship at Columbia University College of Physicians and Surgeons. He holds a PhD in Neuroscience from City University of New York.